News
To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...
After issues with a batch of Jasper Therapeutics' investigational antibody led to "lower" therapeutic effects in several ...
Clinical Trials Arena on MSN6d
Jasper shares decline following trial setback from faulty drug batchJasper Therapeutics’ stock has dropped by more than 50% after the company announced it was looking into the impact of a ...
Stocktwits on MSN6d
Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results ...
Jasper Therapeutics’ dud drug lot has cost half of the biotech's employees their jobs. | Jasper Therapeutics’ dud drug lot ...
Shares of Jasper Therapeutics plummeted in premarket trading Monday after the clinical-stage biotechnology company said issues with one lot of its lead drug candidate briquilimab was disrupting ...
First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical Study in Chronic Inducible Urticaria Planned to Commence in Early 2024 REDWOOD CITY, Calif., Oct. 09 ...
REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback